Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

@article{Cella2006QualityOL,
  title={Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer},
  author={D. Cella and L. Fallowfield and P. Barker and J. Cuzick and G. Locker and A. Howell and O. B. O. A. T. Group},
  journal={Breast Cancer Research and Treatment},
  year={2006},
  volume={100},
  pages={273-284}
}
The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months… Expand

Paper Mentions

Interventional Clinical Trial
Randomized controlled trial to evaluate the impact of yoga on QOL is also powered to evaluate the impact of yoga on survival. Study involves various phases of yoga(divided in three… Expand
ConditionsBreast Cancer Patients
InterventionOther
Interventional Clinical Trial
This study evaluates the effects of progressive relaxation exercises on artralgia, quality of life and anxiety-deppression in breast cancer patients receiving aromatase inhibitor. Half… Expand
ConditionsBreast Cancer
InterventionOther
Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study
TLDR
Improved long-term QoL in postmenopausal Chinese patients with HR+ EBC with AI adjuvant treatment is indicated, which will aid clinicians in optimizing treatment to yield effective healthcare outcomes. Expand
Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review
TLDR
It is suggested that the QOL of post-menopausal women is unlikely to be adversely affected by long-term use of adjuvant endocrine therapy, and efforts are needed to improve the quality of QOL reporting in clinical trials. Expand
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03
TLDR
Continuation of tamoxIFen treatment after adjuvant tamoxifen for 1–4 years may provide Japanese breast cancer patients with better HRQOL than by switching to anastrozole, and there was no statistically significant difference between the treatment groups in the CES-D scores. Expand
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
TLDR
At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping. Expand
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer
TLDR
Neoadjuvant endocrine therapy with LET had no impact on global HRQoL, but did influence endocrine-related symptoms such as hot flush, and the number of patients with clinically significant hot flush increased significantly. Expand
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
TLDR
Given the results of the TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women. Expand
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex', Tamoxifen alone or in combination) trial
TLDR
Compared with commonly accepted thresholds, anastrozole is a cost-effective alternative to generic tamoxifen in adjuvant treatment of postmenopausal women with HR+ early breast cancer from the UK NHS perspective. Expand
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation
TLDR
Clinical benefits of switching to exemestane are accompanied by good overall QoL, and although some symptoms persist, the majority of endocrine symptoms improve after treatment completion. Expand
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
TLDR
Given the similar efficacy of tamoxifen and anastrozole for women older than age 60 years, decisions about treatment should be informed by the risk for serious adverse health effects and the symptoms associated with each drug. Expand
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
TLDR
Less symptom worsening was observed during the first year of extended treatment with the intermittent administration of intermittent letrozole, suggesting an intermittent administration is a safe alternative for women experiencing an increased symptom burden of extended adjuvant endocrine therapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
TLDR
Two years of treatment with anastrozole, tamoxifen, or the combination had a similar overall QoL impact, showing gradual improvement over time. Expand
Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
  • L. Fallowfield, J. Bliss, +5 authors E. Hall
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Results indicate that the clinical benefits of exemestane over tamoxifen are achieved without significant detrimental effect on QOL, and no clinically meaningful differences found between groups in TOI or ES. Expand
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
TLDR
Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer and longer follow-up is required before a final benefit:risk assessment can be made. Expand
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
TLDR
Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Expand
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
TLDR
Exemestane therapy after two to three years ofTamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxIFen treatment. Expand
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
  • T. Whelan, P. Goss, +9 authors H. Muss
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Letrozole did not have an adverse impact on overall QOL and small effects were seen in some domains consistent with a minority of patients experiencing changes in QOL compatible with a reduction in estrogen synthesis. Expand
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B
TLDR
The development and validation of an 18 item endocrine subscale (ES) to accompany a standardised breast cancer quality of life measure, the Functional Assessment of Cancer Therapy (FACT‐B), has acceptable validity and reliability and is sensitive to clinically significant change, making it suitable for clinical trials of endocrine therapy. Expand
Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.
TLDR
Patients who were estrogen receptor-positive, had stage II disease, saw a greater number of breast cancer physicians, and had better perceptions of their abilities to discuss treatment options with physicians had greater odds of tamoxifen use. Expand
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
  • J. Cuzick
  • Medicine
  • Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2003
TLDR
Data from the ATAC adjuvant trial indicate that the aromatase inhibitor anastrozole is more effective than tamoxifen in reducing recurrence and preventing new contralateral tumours, and also has a more favourable side-effect profile. Expand
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
TLDR
The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. Expand
...
1
2
...